Obama should announce scale-up of AIDS treatment programs

Secretary of State Hillary Clinton's recent speech calling for an "AIDS-free generation" through the use of multiple prevention strategies, including more widespread antiretroviral therapy, "was a dramatic reversal of U.S. policy, which has historically viewed treatment more as a costly expense rather than our most powerful prevention investment," physician Loretta Ciraldo and Katrina Ciraldo, a student at Boston University School of Medicine, write in this Miami Herald opinion piece.

"Epidemiologic modeling now shows that if we invest in ending AIDS by scaling up access to treatment, we can prevent 12 million new infections between now and 2020. That's ... 12 million steps closer to an AIDS free world," they write, concluding, "PEPFAR has almost reached the treatment goal it set for 2013, so President Obama should take the next step and announce bold and concrete plans to scale-up treatment. Doing so on World AIDS Day, he could demonstrate to the rest of the world that we must take advantage of this unique turning point in history" (11/22). 


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Gene therapy trial: restored hearing in children with hereditary deafness